GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Cyclically Adjusted PS Ratio

AtriCure (AtriCure) Cyclically Adjusted PS Ratio : 3.28 (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is AtriCure Cyclically Adjusted PS Ratio?

As of today (2024-05-16), AtriCure's current share price is $22.525. AtriCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $6.86. AtriCure's Cyclically Adjusted PS Ratio for today is 3.28.

The historical rank and industry rank for AtriCure's Cyclically Adjusted PS Ratio or its related term are showing as below:

ATRC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.54   Med: 5.47   Max: 15.67
Current: 3.22

During the past years, AtriCure's highest Cyclically Adjusted PS Ratio was 15.67. The lowest was 1.54. And the median was 5.47.

ATRC's Cyclically Adjusted PS Ratio is ranked worse than
59.92% of 474 companies
in the Medical Devices & Instruments industry
Industry Median: 2.185 vs ATRC: 3.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AtriCure's adjusted revenue per share data for the three months ended in Mar. 2024 was $2.330. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AtriCure Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AtriCure's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Cyclically Adjusted PS Ratio Chart

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.37 10.70 12.25 7.15 5.28

AtriCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.49 7.54 6.55 5.28 4.43

Competitive Comparison of AtriCure's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, AtriCure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AtriCure's Cyclically Adjusted PS Ratio falls into.



AtriCure Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AtriCure's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.525/6.86
=3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AtriCure's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.33/131.7762*131.7762
=2.330

Current CPI (Mar. 2024) = 131.7762.

AtriCure Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.988 100.560 1.295
201409 0.991 100.428 1.300
201412 1.092 99.070 1.453
201503 1.104 99.621 1.460
201506 1.193 100.684 1.561
201509 1.144 100.392 1.502
201512 1.170 99.792 1.545
201603 1.146 100.470 1.503
201606 1.256 101.688 1.628
201609 1.209 101.861 1.564
201612 1.294 101.863 1.674
201703 1.289 102.862 1.651
201706 1.401 103.349 1.786
201709 1.294 104.136 1.637
201712 1.410 104.011 1.786
201803 1.427 105.290 1.786
201806 1.558 106.317 1.931
201809 1.486 106.507 1.839
201812 1.449 105.998 1.801
201903 1.459 107.251 1.793
201906 1.578 108.070 1.924
201909 1.496 108.329 1.820
201912 1.605 108.420 1.951
202003 1.376 108.902 1.665
202006 0.980 108.767 1.187
202009 1.244 109.815 1.493
202012 1.307 109.897 1.567
202103 1.328 111.754 1.566
202106 1.585 114.631 1.822
202109 1.528 115.734 1.740
202112 1.586 117.630 1.777
202203 1.638 121.301 1.779
202206 1.850 125.017 1.950
202209 1.817 125.227 1.912
202212 1.917 125.222 2.017
202303 2.028 127.348 2.099
202306 2.181 128.729 2.233
202309 2.118 129.860 2.149
202312 2.294 129.419 2.336
202403 2.330 131.776 2.330

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AtriCure  (NAS:ATRC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AtriCure Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AtriCure's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director